What is the recommended oral and intravenous amiodarone dosing regimen for atrial fibrillation, including loading, maintenance, and hepatic impairment adjustments?

Amiodarone Dosing for Atrial Fibrillation

For atrial fibrillation, use intravenous amiodarone 150-300 mg over 1 hour followed by 10-50 mg/hour (or 0.5 mg/min) for 24 hours, then transition to oral maintenance of 100-200 mg daily after completing a loading regimen of 600-800 mg/day until 10 grams total is achieved. 1

Intravenous Dosing

Acute Rate Control or Rhythm Control

• Loading dose: 150-300 mg IV over 1 hour 1
• Maintenance infusion: 10-50 mg/hour (0.5 mg/min = 720 mg/24 hours) 1
• Maximum initial infusion rate: Do not exceed 30 mg/min 2
• Duration: Maintenance infusion can continue for 2-3 weeks regardless of age, renal function, or left ventricular function 2

Breakthrough Episodes

• Supplemental bolus: 150 mg in 100 mL D5W over 10 minutes for breakthrough VF or hemodynamically unstable VT 2
• This same supplemental dosing can be applied for recurrent AF episodes 1

Critical Administration Details

• Must use volumetric infusion pump (drop counters can underdose by up to 30%) 2
• Concentrations >2 mg/mL require central venous catheter to avoid phlebitis 2
• Use in-line filter during administration 2
• Administer in glass or polyolefin bottles (not evacuated glass containers) 2
• Mean daily doses >2100 mg associated with increased hypotension risk 2

Oral Dosing

Loading Phase

• 600-800 mg/day in divided doses until 10 grams total administered 1
• Alternative: 800-1,600 mg/day for ventricular arrhythmias 1
• Loading duration: Typically 6-10 grams over 2-4 weeks 1
• Can combine IV and oral dosing to complete loading 1

Maintenance Phase

• Standard maintenance: 200 mg daily 1
• Range: 100-200 mg daily 1
• Some patients may require 200-400 mg daily for ventricular arrhythmias 1

Transition from IV to Oral

The transition depends on duration of IV therapy 1:

• <1 week IV: Start 800-1,600 mg/day oral
• 1-3 weeks IV: Start 600-800 mg/day oral
• >3 weeks IV: Start 400 mg/day oral

Hepatic Impairment Adjustments

No specific dosage adjustments are provided in the FDA labeling for hepatic impairment 2, 3. However, critical monitoring is essential:

• Baseline liver transaminases required before initiation 1
• Monitor ALT/AST every 6 months during maintenance therapy 1
• Hepatocellular necrosis and acute renal failure have occurred with excessively rapid IV loading infusions 2
• Consider using lowest effective dose given hepatic metabolism and risk of hepatotoxicity 1

Key Monitoring Requirements

Baseline Assessment 1

• Complete history and physical (focus on heart failure, arrhythmia symptoms)
• 12-lead ECG with QTc calculation
• Thyroid studies (TSH, free T4)
• Liver transaminases (ALT, AST)
• Chest radiograph
• Pulmonary function tests including DLCO
• Digoxin level if applicable
• PT/INR if on warfarin

During IV Administration 2

• Continuous ECG monitoring for bradycardia (occurs in 4.9%) and heart block 1
• Blood pressure monitoring (hypotension occurs in 16% with IV) 1
• Reduce or discontinue infusion if bradycardia, heart block, or hypotension develops 1

Maintenance Monitoring (Every 6 Months) 1

• Thyroid studies and liver transaminases
• History and physical for adverse effects
• Digoxin level if applicable
• Chest radiograph and PFTs if pulmonary symptoms develop
• Ophthalmologic exam if visual symptoms

Important Clinical Considerations

Drug Interactions

• Warfarin: Reduces clearance; peak interaction at 7 weeks; monitor PT/INR weekly for first 6 weeks 1
• Digoxin: Levels predictably double; reduce digoxin dose by 50% 1
• Beta-blockers and calcium channel blockers: Enhanced bradycardia risk 1

Contraindications

• Second- or third-degree heart block without pacemaker 1
• Severe bradycardia without pacemaker 2

Efficacy Expectations

• IV amiodarone: Rhythm effect occurs in <30 minutes; conversion may take up to 24 hours 1
• Conversion rates: 80-87% with proper loading regimens 4
• Rate control: More immediate and predictable than cardioversion; occurs after first 300-400 mg 5
• Most conversions occur after 6-8 hours of therapy initiation 6

Common Pitfalls

• Pulmonary toxicity is the most serious adverse effect (1% annually with proper dosing) 1
• Bradycardia and QT prolongation are common but torsades de pointes is rare 1
• Phlebitis risk with peripheral IV concentrations >2.5 mg/mL 2
• Use lowest effective maintenance dose to minimize cumulative toxicity 1

Special Populations

• Structural heart disease/heart failure: Amiodarone is preferred over class IC agents (flecainide, propafenone) which are contraindicated 6
• Renal impairment: No dose adjustment needed (renally eliminated drugs like atenolol and digoxin require adjustment) 1
• Elderly: No specific dose adjustment but increased monitoring warranted 2